Top 5 metastatic breast cancer stories

In honor of October 13 as National Metastatic Breast Cancer Awareness Day, Contemporary OB/GYN® has collected its top metastatic breast cancer articles over the past year.

1. FDA grants trastuzumab deruxtecan breakthrough therapy designation for breast cancer

The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.

2. FDA approves pembrolizumab for metastatic triple-negative breast cancer

Merck earned a new indication for pembrolizumab (Keytruda), in combination with chemotherapy, to treat locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC).

3. Survival benefit in advanced or metastatic breast cancer with visceral metastases

Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.

4. Combination therapy for treatment of germline BRCA-mutated metastatic breast cancer

Results from the study showed antitumor activity and safety to be similar to olaparib and durvalumab monotherapy outcomes.

5. PD-L1 CNA as a biomarker in metastatic breast cancer

Australian researchers believe that PD-L1 may have potential as an indicator of potential response to chemotherapy in women with metastatic breast cancer. That was based on results of a randomized trial, presented at the European Society for Medical Oncology in Lugano, Switzerland.